AstraZeneca Advances Shanghai as the 'Home Port' for Chinese Pharma Innovation Going Global

What is the significance of the Chinese market to leading biopharmaceutical companies? Pascal Soriot, Chief Executive Officer of AstraZeneca PLC, one of the world's leading biopharmaceutical companies, stated in an interview on the 26th: "China plays a vital role in the global healthcare industry, leading in innovation and playing a key role in the global research, development, and production of important drugs. For AstraZeneca, the Chinese market is crucial."

 

On the same day, the "2024 Shanghai BioPharmaceuticalsAt the "International Industrial Development Conference," AstraZeneca officially announced that Shanghai has become its fifth global strategic center. "Shanghai Biomedical InnovationEnterprise"2024 International Collaboration Plan" officially launched on the same day, empowering locally innovated drugs to reach new heights and assisting Chinese innovation in leading global pharmaceutical advancements.

 

It is reported that in the future, Shanghai, China will become another global strategic center for AstraZeneca, integrating R&D, commercial operations, and production, in addition to its four major R&D-focused strategic centers: Cambridge in the UK, Boston and Gaithersburg in the US, and Gothenburg in Sweden. It will serve as a crucial strategic pivot for AstraZeneca's global strategy, R&D, and long-term development.

 

It is reported that biomedicine is one of the three leading industries that Shanghai focuses on developing. Shanghai is one of the innovation hubs for China's modern pharmaceutical industry, with comprehensive development elements, a complete industrial ecosystem, and increasing international influence. In recent years, Shanghai has made significant progress in the development of its biomedicine industry, with the industry scale growing by 4.9% year-on-year in 2023. The "2024 Shanghai Biomedical Industry International Development Conference," held that day, had the theme "Facing the World, Sailing Together Abroad." It aimed to promote dialogue and exchanges in the biomedicine field, explore multilateral industrial cooperation, and advance the internationalization and high-quality development of Shanghai's medical industry.

 

During the interview, the reporter learned that the "2024 Shanghai Biomedical Innovation Enterprises Cooperation Overseas Expansion Plan" aims to deepen cooperation with China's local innovative forces and continuously build an important platform for going global. The plan will cover emerging markets in Belt and Road partner countries as well as countries in Europe, America, and Japan. Through reciprocal visits and对接s, it will support 30 outstanding Shanghai enterprises in expanding overseas, promoting cross-border cooperation and exchange in pharmaceutical innovation. AstraZeneca stated that it will actively help Shanghai become the origin of pharmaceutical innovation achievements and the "home port" for China’s innovative expansion overseas.

 

It is reported that this initiative will further expand the international market for Shanghai's medical innovation companies. By innovating "going global," it will strengthen the connection between Shanghai and the international innovation ecosystem, enhancing Shanghai's international reputation as a science and technology innovation hub. The launch event brought together business leaders from AstraZeneca’s Latin America, Middle East & Africa, and Asia regions, as well as guest representatives from six local innovative pharmaceutical companies.

 

As an important city participating in international competition and innovative cooperation in the biopharmaceuticals industry, Shanghai is accelerating its development into a globally influential science and innovation hub, providing crucial support for local medical innovation companies to advance on the path to internationalization. The government strongly supports original innovation and has been increasing investment in basic research year by year. In recent years, Shanghai has remained committed to being a source of innovation, actively promoting biopharmaceutical companies to expedite the processes of research and development, industrialization, commercialization, and globalization.

 

This conference connects renowned individuals from multiple fields including industry, academia, research, medicine, and finance, actively promoting in-depth exchange of ideas and multi-dimensional communication across the industrial chain, injecting innovative momentum into Shanghai's biopharmaceuticals industry. During the conference, two roundtable meetings were held, attended by government leaders, members of the Chinese Academy of Sciences and the Chinese Academy of Engineering, university professors, senior executives from domestic and international biopharmaceutical companies, heads of multinational industry organizations, and leaders of top investment firms to discuss the path of innovation and development in the biopharmaceutical sector.

 

Shanghai Municipal Science and Technology Commission announced that the next step for Shanghai will be to adhere to the systematic advancement of the "R&D + Clinical + Manufacturing + Application" full industrial chain system. The main focus will be on enhancing innovation-driven capabilities, seizing key opportunities presented by new paradigms and the opening of new tracks. High-level innovation platforms and carriers will serve as crucial support, gathering top-tier resources in scientific and industrial innovation, improving clinical research capabilities, accelerating the cultivation of leading biopharmaceutical enterprises, and promoting the "going global" of innovative products. Shanghai will use key areas such as Pudong New Area and Minhang District as carriers to promote the distinctive, intensive, and large-scale development of industrial parks. At the same time, it will strengthen policy support, expedite product launches, promotion, and application, and accelerate the construction of a globally influential biopharmaceutical industry innovation hub and a world-class biopharmaceutical industry cluster.

 

On the same day, AstraZeneca also joined hands with Zhongshan Hospital Affiliated to Fudan UniversityHospitalLaunch the "Green Ribbon Liver Cancer Early Screening and Diagnosis Program" to help create an innovative model for early liver cancer screening. It is reported that the program, led by Zhongshan Hospital Affiliated to Fudan University, with Fan Jia, academician of the Chinese Academy of Sciences and president of Zhongshan Hospital Affiliated to Fudan University, and Zhou Jian, vice president of Zhongshan Hospital Affiliated to Fudan University, as the main leaders, will comprehensively promote the screening of high-risk groups for liver cancer, verification of new technologies for early liver cancer screening, promotion of standardized diagnosis and treatment of liver cancer, and carry out public...DiseaseScience Popularization Education.